{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078577","form_type":"8-K","ticker":"LIMN","cik":"0001971387","company_name":"Liminatus Pharma, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.725292+00:00","generated_at":"2026-05-17T13:36:52.249794+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Liminatus Pharma provides IBA101 strategic update targeting PD-1/L1 patent cliff partnership opportunities","bullets":["IBA101 is a CD47 mAb designed to avoid RBC/platelet binding, eliminating cytopenia that derailed Hu5F9 and lemzoparlimab.","Preclinical data shows IBA101 + anti-PD-1 combination produces synergistic anti-tumor response with favorable safety.","Company claims it is the only U.S.-based firm developing a CD47 blocker with a validated safety profile.","PD-1/L1 inhibitors Keytruda (Merck) and Opdivo (BMS) face core patent expiry by 2028; others (Tecentriq, Imfinzi, Libtayo) by 2030.","Strategy positions IBA101 as a patent-protected synergistic partner to extend PD-1/L1 franchise lifecycles."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078577","json":"https://secwatch.observer/filing/0001104659-25-078577.json","markdown":"https://secwatch.observer/filing/0001104659-25-078577.md","text":"https://secwatch.observer/filing/0001104659-25-078577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925078577/0001104659-25-078577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465925078577/tm2523534d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:36:52.249794+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}